Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Transactions
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Inozyme Pharma, Inc. (INZY) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/03/2023 4 Subramanian Sanjay (SVP, CFO) has filed a Form 4 on Inozyme Pharma, Inc.
Txns: Granted 2,319 shares @ $3.57, valued at $8.3k
09/26/2023 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Inozyme Pharma Announces Positive Interim Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ENPP1 Deficiency and ABCC6 Deficiency - Data from ongoing trial suggest clinical benefit for ENPP1 Deficiency, including improvement in key biomarkers, patient reported outcomes and functional outcomes - - Improvement in the Global Impression of Change observed in all three dose cohorts in ABCC6 Deficiency trial - - INZ-701 was generally well tolerated and exhibited a favorable safety and immunogenicity profile in both trials - - Company to host conference call and webcast today at 8:00 a.m. ET -"
08/11/2023 SC 13D/A Longitude Capital Partners III, LLC reports a 9.9% stake in INOZYME PHARMA, INC.
08/08/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/08/2023 8-K Quarterly results
Docs: "Inozyme Pharma Reports Second Quarter 2023 Financial Results and Provides Business Highlights – Interim data readouts from ongoing Phase 1/2 trials of INZ-701 in adults with ENPP1 Deficiency and ABCC6 Deficiency expected in September 2023 – – Plasma pyrophosphate to serve as primary endpoint in the U.S. and co-primary endpoint in the EU for ENERGY-3 pediatric pivotal trial for ENPP1 Deficiency; initiation expected in October 2023 – – Cash, cash equivalents, and short-term investments as of June 30, 2023, together with proceeds from July 2023 offering, expected to fund cash flow requirements into the fourth quarter of 2025 –"
08/07/2023 SC 13D/A Pivotal bioVenture Partners Fund I, L.P. reports a 9.5% stake in Inozyme Pharma, Inc.
08/03/2023 4 Pivotal bioVenture Partners Fund I, L.P. (Director) has filed a Form 4 on Inozyme Pharma, Inc.
Txns: Bought 119,048 shares @ $4.8, valued at $571.4k
Bought 714,285 shares @ $4.8, valued at $3.4M
08/03/2023 4 Hopfner Robert Lorne (Director) has filed a Form 4 on Inozyme Pharma, Inc.
Txns: Bought 119,048 shares @ $4.8, valued at $571.4k
Bought 714,285 shares @ $4.8, valued at $3.4M
07/28/2023 8-K Quarterly results
07/28/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
07/27/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
07/26/2023 8-K Quarterly results
05/31/2023 SC 13G MILLENNIUM MANAGEMENT LLC reports a 5.2% stake in INOZYME PHARMA, INC.
05/23/2023 SC 13D/A Pivotal bioVenture Partners Fund I, L.P. reports a 8.3% stake in Inozyme Pharma, Inc.
05/15/2023 4 Hopfner Robert Lorne (Director) has filed a Form 4 on Inozyme Pharma, Inc.
Txns: Bought 219,230 shares @ $6.48, valued at $1.4M
Bought 228,702 shares @ $6.25, valued at $1.4M
05/09/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/09/2023 8-K Quarterly results
Docs: "Inozyme Pharma Reports First Quarter 2023 Financial Results and Provides Business Highlights - Upcoming clinical and regulatory milestones remain on track with previous guidance – - Current cash, cash equivalents and short-term investments anticipated to fund cash flow requirements into the fourth quarter of 2024 - BOSTON, May 9, 2023 – Inozyme Pharma, Inc. , a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today reported financial results for the first quarter ended March 31, 2023, and provided business highlights. “We are continuing to advance INZ-701 and look forward to initiating a pivotal trial for pediatric patients with ENPP1 Deficiency in the third quarter of this y..."
05/03/2023 4 Bolte Axel (Director) has filed a Form 4 on Inozyme Pharma, Inc.
Txns: Granted 100,000 options to buy @ $5.81, valued at $581k
04/27/2023 ARS Form ARS - Annual Report to Security Holders:
04/27/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/27/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/04/2023 4 Treco Douglas A (CEO) has filed a Form 4 on Inozyme Pharma, Inc.
Txns: Granted 800,000 options to buy @ $0
Granted 100,000 restricted stock units @ $0
04/04/2023 SC 13D/A Pivotal bioVenture Partners Fund I, L.P. reports a 7.4% stake in Inozyme Pharma, Inc.
04/04/2023 4 Bolte Axel (Director) has filed a Form 4 on Inozyme Pharma, Inc.
Txns: Granted 4,806 shares @ $2.21, valued at $10.6k
04/04/2023 4 Subramanian Sanjay (SVP, CFO) has filed a Form 4 on Inozyme Pharma, Inc.
Txns: Granted 979 shares @ $2.21, valued at $2.2k
04/04/2023 4 Winton Matthew (COO) has filed a Form 4 on Inozyme Pharma, Inc.
Txns: Granted 250,000 options to buy @ $5.39, valued at $1.3M
04/04/2023 3 Winton Matthew (COO) has filed a Form 3 on Inozyme Pharma, Inc.
03/29/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
03/27/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
03/22/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/22/2023 10-K Annual Report for the period ended December 31, 2022
03/22/2023 8-K Quarterly results
03/10/2023 8-K Regulation FD Disclosure  Interactive Data
03/07/2023 SC 13G SPHERA FUNDS MANAGEMENT LTD. reports a 5.2% stake in Inozyme Pharma Inc.
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy